Phase IIb study of sapacitabine in older patients with myelodysplastic syndrome who have failed prior hypomethylating agent therapy

Trial Profile

Phase IIb study of sapacitabine in older patients with myelodysplastic syndrome who have failed prior hypomethylating agent therapy

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2016

At a glance

  • Drugs Sapacitabine (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors Cyclacel Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2016 As per a Cyclacel media release, the company expects to start this trial in 2016.
    • 11 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top